Spinal Cord Injury
Conditions
Keywords
Insulin, Intranasal, Safety, Feasibility, Spinal Cord Injury, SCI, INI
Brief summary
The purpose of this study is to find out whether insulin, a drug approved by the FDA for the treatment of diabetes mellitus, is safe when administered as a nasal spray (intranasally) to people who have experienced a spinal cord injury. While insulin nasal spray has been shown to be safe in many patient populations, it has not yet been studied in people with spinal cord injury. This study would be the first step to developing insulin nasal spray as a treatment for spinal cord injury in the future. This study is recruiting up to 12 individuals who have experienced a spinal cord injury at least 4 months ago to administer either 76 IU insulin nasal spray or a placebo (inactive nasal spray) at home every day for up to 24 days. Participants will be asked questions about their health and symptoms related their spinal cord injury, and will have their blood collected throughout the study. Participants who are unable to administer the medication independently must have a study partner in order to participate.
Interventions
DRUGRegular Insulin
Administered Intranasally at 76 IU
OTHER0.9 % Normal Saline
Placebo Control
Sponsors
HealthPartners Institute
Uniformed Services University of the Health Sciences
Department of Defense Congressionally Directed Medical Research Program
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Intervention model description
Participants will be randomized 1:1 into one of 2 groups: 76 IU insulin, or saline (placebo) control
Eligibility
Sex/Gender
ALL
Age
18 Years to 84 Years
Healthy volunteers
No
Inclusion criteria
1. Subject is ≥18 and \<85 years of age 2. Subject has sustained a traumatic or non-traumatic spinal cord injury with American Spinal Injury Association (ASIA) rating A, B, C or D, complete or incomplete 3. Subject sustained spinal cord injury at least 4 months before baseline visit 4. Female subjects must have either: (1) a negative pregnancy test at the screening and treatment visits OR (2) be at least 2 years post-menopausal / surgically sterile 5. The subject must be proficient in English in order to comply with instructions and measures for the study 6. Subject is able to prepare and administer the study drug as outlined in the protocol or has a carer who is available to do so for the duration of the study 7. Subject can provide written informed consent 8. Subject has been on a stable regimen of medications for at least 30 days from baseline visit
Exclusion criteria
1. Subject is dependent on a ventilator or has a patent tracheostomy site 2. Subject has recent history (within past 6 months) of recurrent autonomic dysreflexia, defined as a sudden rise in systolic BP greater than 20 mmHg or diastolic BP greater than 10 mmHg without rise in heart rate and accompanied by symptoms such as headache, facial flushing, sweating, nasal congestion, or blurry vision 3. Subject has medical history and/or clinically determined disorders: chronic sinusitis, previous nasal and/or oto-pharyngeal surgery and severe deviated septum and/or other anomalies 4. Subject has history of any of the following: active and significant central nervous system, psychiatric illness, pulmonary, or cardiovascular disorders or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by investigator 5. Subject has participated in a clinical trial investigation within 3 months of this study 6. Subject has a history of allergy, hypersensitivity, or other significant adverse reaction to insulin 7. Subject is taking insulin for Type I or Type II diabetes 8. Subject is pregnant or breast feeding 9. Any other clinically relevant finding that would pose a safety risk to the subject as determined by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety measured by number of serious adverse events (SAE) and adverse events (AE) | 3 weeks | Total number of AEs/SAEs during the course of treatment. More AEs/SAEs indicates a less safe treatment. AEs counts will include total count and will be stratified by severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment adherence as assessed by participant Daily Drug Diaries | 3 weeks | Number of doses successfully administered as reported by participants in their daily drug diaries |
| Feasibility of virtual training as assessed by the Virtual Training Compliance Checklist | Baseline Visit | Average score on virtual training compliance checklist, both arms combined |
| Acceptability of virtual training as assessed by the Virtual Training and Feasibility and Acceptability Survey | Baseline | Total score on the Virtual Training Feasibility and Acceptability Survey, both arms combined |
| Feasibility of blood spot collection procedure as measured by a Blood Spot Procedure Compliance Checklist | Screening Visit | Participants will be trained to perform a blood spot collection procedure independently. Feasibility will be measured by the average score on blood spot procedure compliance checklist, both arms combined |
| Acceptability of Blood Spot Procedure, as measured by a Blood Spot Procedure Post-Training Acceptability Survey | Screening Visit | Acceptability of performing blood spot procedure independently will be measured by the average score on a blood spot procedure post-training acceptability survey, both arms combined |
Countries
United States
Contacts
CONTACTMeghan E O'Brien, MPH
CONTACTBethany K Crouse, PhD
PRINCIPAL_INVESTIGATORLeah R Hanson, PhD
HealthPartners Institute
PRINCIPAL_INVESTIGATORKimberly Byrnes, PhD
Uniformed Services University of the Health Sciences
Outcome results
None listed